Innovent Biologics (HKG:1801) said its collaboration with Eli Lilly has become effective after receiving early clearance from the U.S. Federal Trade Commission, according to a Wednesday Hong Kong bourse filing.
All conditions precedent have been fulfilled, with the agreement taking effect on Tuesday.
The biological company also clarified that recent media reports suggesting the collaboration involves an acquisition are incorrect, adding it has no intention to pursue such a transaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments